Andes hantavirus cardiopulmonary syndrome, transmitted by Oligoryzomys longicaudatus, has no approved treatment, a case fatality rate of 35%, and documented person-to-person transmission. An Andes vaccine, highly needed for prevention, is in development. We aimed to evaluate knowledge, attitudes and practices (KAP) regarding hantavirus disease and willingness to participate in a future Andes vaccine trials through a cross sectional face-to-face oral survey of a randomly selected adult sample from 2 rural communes in southern Chile. Human subjects approval was obtained from our institutional IRBs, and participants signed informed consent. We enrolled 319 subjects from Corral and 321 from Curarrehue; 98% had heard about hantavirus disease and its reservoir but only half knew about transmission, symptoms and prevention. Participants fear the disease but are only partially aware of their own risk. One third of participants reported presence of rodents inside their homes. Despite moderate confidence in their health system, most subjects perceived vaccines as beneficial, and 93% would accept an approved hantavirus vaccine. Half would agree to participate in a vaccine trial and 29% would allow their children to participate. Motivations to participate were mainly altruistic, while risk perception was the main reason for declining. Knowledge about hantavirus disease and prevention practices require reinforcement, and a vaccine trial seems feasible in these populations.

The potential incubation period from exposure to onset of symptoms was 7–39 days (median 18 days) in 20 patients with a defined period of exposure to Andes virus in a high-risk area. This period was 14–32 days (median 18 days) in 11 patients with exposure for <48 hours.

Background: Filamentous fungi are an emergent cause of severe infections in immunocompromised patients. Timely and accurate identification is crucial to initiate appropriate therapy. Traditional identification methods are time-consuming, labor-intensive, and operator-dependent. Ma-trix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry is a rapid and easy-to-perform identification method. This study evaluates the effectiveness of a commercial MALDI-TOF MS platform to identify filamentous fungi in a routine laboratory. Material and Methods: We included 67 fungal isolates from 35 species/species complexes within 15 genera, confirmed in mycology reference laboratories. 33 were from clinical samples and 34 from strain collections. The study used the VITEK MS system (v3.2.0 database), after sample extraction by VITEK MS Mould Kit. Results were classified into categories: ‘correct species’, ‘correct species complex’, ‘correct genus’, ‘incorrect identification’, and ‘no identification’. We also evaluated the practicality of the kit. Results: VITEK MS correctly identified 91.0% of isolates (58.2% to species, 29.9% to species complex, and 1.5% to genus level). In 82%, the result matched the species/species complex identified by reference methods. No misidentifications were observed. The kit was rapid and easy to use. Conclusion: The VITEK MS system showed a high capability to accurately identify filamentous fungi in a routine laboratory.